Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTEG- Bloodless Glucose Monitor -- Ignore unavailable to you. Want to Upgrade?

To: nestegg who wrote (144)	6/9/1998 12:55:00 PM
From: DryHeat	Read Replies (1) \| Respond to of 176

If the product works as well as the current sensors I see it replacing them in all applications and costing the same due to insurance company pressure. How many, and how soon I can not even guess.

To: nestegg who wrote (144)	6/10/1998 9:56:00 AM
From: BitWizrd	Read Replies (1) \| Respond to of 176

As for NTEG potential... From Volpe Brown Whelan & Co. Equity Research: "In the United States alone, we estimate more than 8.8 million people have been diagnosed with diabetes and approximately an equal number have the disease but have not yet been diagnosed. [W]e forecast that the worldwide market [for BGMs] will grow to $5.9 billion in 2002. "We believe the LifeGuide system will make a limited impact in the diabetes marketplace due to the system's marginal improvement in invasiveness and convenience over current finger-stick methods."